Genentech TNKase/ReoPro Study Looking At New Use For Activase Successor
Executive Summary
FDA wants Genentech to move promptly to update labeling for its Activase-successor product TNKase once data from ongoing combination therapy trials are available.
You may also be interested in...
Large Comparative Trials Deserve More Support, FDAer Says
Thrombolytic agent mortality studies demonstrate the value of large head-to-head trials to detect small outcomes differences between drugs, Center for Drug Evaluation & Research Acting Deputy Director Mark Goldberger said
Large Comparative Trials Deserve More Support, FDAer Says
Thrombolytic agent mortality studies demonstrate the value of large head-to-head trials to detect small outcomes differences between drugs, Center for Drug Evaluation & Research Acting Deputy Director Mark Goldberger said
Actelion Is Building 50-Rep U.S. Sales Force For Tezosentan, TNKase
The Swiss pharmaceutical company Actelion plans to have a 50-rep sales force in the U.S. by the middle of 2001 to support the launch of Genentech's TNKase and its own tezosentan.